Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections

Urinary tract infections represent a major public health problem as the rapid emergence of antibiotic-resistant strains among uropathogens is causing the failure of many current treatments. The use of bacteriophages (phages) and their derivatives to combat infectious diseases is an old approach that...

Full description

Saved in:
Bibliographic Details
Published in:Antibiotics (Basel) 2020-08, Vol.9 (8), p.466
Main Authors: de Miguel, Trinidad, Rama, José Luis R., Sieiro, Carmen, Sánchez, Sandra, Villa, Tomas G.
Format: Article
Language:English
Subjects:
Antibiotic resistance
Antibiotics
Bacteria
Bacterial infections
Bacteriophages
Biofilms
Clinical medicine
Clinical trials
Drug resistance
E coli
Enzymes
Health aspects
Immune system
In vivo methods and tests
Infections
Infectious diseases
Lysins
Lytic enzymes
Pathogens
phage therapy
phage-antibiotic synergy (PAS)
Phages
Physiological aspects
Public health
Review
Staphylococcus infections
Strains (organisms)
Therapy
Urinary tract
Urinary tract diseases
Urinary tract infections
urinary tract infections (UTIs), uropathogens
Urogenital system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Urinary tract infections represent a major public health problem as the rapid emergence of antibiotic-resistant strains among uropathogens is causing the failure of many current treatments. The use of bacteriophages (phages) and their derivatives to combat infectious diseases is an old approach that has been forgotten by the West for a long time, mostly due to the discovery and great success of antibiotics. In the present so-called “post-antibiotic era”, many researchers are turning their attention to the re-discovered phage therapy, as an effective alternative to antibiotics. Phage therapy includes the use of natural or engineered phages, as well as their purified lytic enzymes to destroy pathogenic strains. Many in vitro and in vivo studies have been conducted, and these have proved the great potential for this therapy against uropathogenic bacteria. Nevertheless, to date, the lack of appropriate clinical trials has hindered its widespread clinic application.
ISSN:2079-6382
2079-6382
DOI:10.3390/antibiotics9080466